Valued at USD 12.66 billion in 2023, the intravenous immunoglobulin market is projected to reach USD 13.57 billion in 2024 and USD 24.13 billion by 2032, growing at a CAGR of 7.50% during the forecast period 2024–2032. Immunoglobulins, commonly called antibodies, are glycoproteins produced by white blood cells and plasma that detect and bind to antigens such as bacteria and viruses. IVIG therapy introduces antibodies from healthy individuals into a patient's bloodstream, where they can neutralize pathogens and enhance immune responses. North America led the global market in 2022.

Rising Immunodeficiency Disorders Drive Intravenous Immunoglobulin Market Growth

The report identifies the growing number of people suffering from immunodeficiency disorders as the key growth driver. Improved diagnostic techniques, increased awareness, and better understanding among healthcare professionals have raised detection rates, while advances in medical treatment allow affected individuals to live longer, increasing overall case numbers. Immunoglobulin, derived from human blood plasma and containing a concentrated dose of antibodies, is a commonly used treatment. It is administered intravenously to replace or supplement antibodies in individuals with immunodeficiency.

Technology and Market Structure

Growth is further supported by advancements in plasma collection and fractionation technologies and by greater awareness of IVIG benefits among healthcare professionals and patients. The ecosystem includes pharmaceutical companies that manufacture IVIG products, plasma collection centers, contract manufacturing organizations, distributors, hospitals, clinics, and patients. The market is competitive, with both branded and generic products, and is shaped by regulatory policies, reimbursement systems, and regional dynamics. Expanding healthcare expenditure and a rising geriatric population also underpin demand. Major pharmaceutical companies typically operate dedicated divisions or subsidiaries that produce and promote IVIG products.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/global-intravenous-immunoglobulin-market

IgG Leads Component Segmentation

By component, the market is segmented into IgG, IgA, IgM, IgE, and IgD. The IgG segment is expected to be the largest during the forecast period. Extensive clinical research has driven widespread use and acceptance in medical practice, and numerous clinical trials have demonstrated the effectiveness and safety of IgG in treating autoimmune disorders, neurological conditions, and other immune-related diseases. IVIG combines immunoglobulins from multiple donors and is delivered through intravenous infusion.

Primary Immunodeficiency and Hospital Pharmacies Shape Demand

Immunodeficiency diseases accounted for the largest application share in 2022. They are classified as primary (inherited) or secondary (acquired), and patients with primary immunodeficiency conditions such as common variable immunodeficiency, X-linked agammaglobulinemia, and severe combined immunodeficiency are commonly prescribed IVIG. Better diagnostic methods and early detection are identifying more patients, and timely treatment has improved outcomes.

By distribution channel, hospitals accounted for the highest share in 2022. Hospital pharmacies monitor patients receiving IVIG therapy, collaborate with healthcare professionals to track patient progress, and report adverse events or reactions to the appropriate regulatory bodies.

Regional Analysis: North America Leads, Asia Pacific Expands

North America dominated in 2022, supported by advanced healthcare infrastructure, heavy R&D and clinical trial investment by major pharmaceutical companies, and the presence of key players such as Baxter International Inc. Rising awareness drives early diagnosis and treatment initiation. Asia Pacific is expected to grow significantly, given its large population, including India and China, a competitive field of local and international producers, increasing government support, and healthcare reforms. The region's well-developed hospitals, clinics, and research facilities facilitate widespread adoption of IVIG therapies.

Key Players in the Intravenous Immunoglobulin Market

Major players intravenous immunoglobulin include Baxter International Inc.; BDI Pharma Inc.; Biotest AG; China Biologics Products Inc.; CSL Behring; Grifols SA; Kedrion Biopharma; LFB Biotechnologies; and Octapharma AG. In June 2025, Takeda announced FDA approval of GAMMAGARD LIQUID ERC as a replacement treatment for primary immunodeficiency in patients aged two years and older. In September 2023, Biotest received UK approval for Yimmugo. The report notes challenges including high therapy cost, potential side effects, and plasma supply constraints.

More Trending Latest Reports By Polaris Market Research:

healthy-snacks-market

ammonia-market

top-10-health-food-companies-will-change-the-food-industry-in-upcoming-years

industrial-coatings-market

digital-payment-market

bioethanol-market

airport-services-market

electrolyzer-market

customer-experience-business-process-outsourcing-market